| CAS: | 256376-24-6 | |
| 分子式: | C20H17FN6 | |
| 分子量: | 360.39 | |
| 英文名称: |
| |
| 用途: | BAY 41-2272是一种直接的,且独立于NO的水溶性guanylate cyclase (sGC)激动剂。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | 详情 | ||||||||||||||||||||||||||||||||
| B793011 | MACKLIN | BAY 41-2272 | 10mM in DMSO | 684元/1ml; | 展开 | ||||||||||||||||||||||||||||||||
储存:-20°C | |||||||||||||||||||||||||||||||||||||
| B872987 | MACKLIN | BAY 41-2272 | 99% | 570元/5mg; 1412元/25mg; | 展开 | ||||||||||||||||||||||||||||||||
储存:-20℃ 状态:白色到灰白色固体 | |||||||||||||||||||||||||||||||||||||
| 196876 | Sigma-Aldrich | BAY 41-2272-CAS 256376-24-6-Calbiochem | A cell-permeable pyrazolopyridinylpyrimidine compound that acts as a selective and potent stimulator of soluble guanylate cyclase (effective dose ~ 0.1 nM to 100 µM using recombinant soluble guan | 2498.15元/5 MG; | 展开 | ||||||||||||||||||||||||||||||||
产品说明 一般描述 A cell-permeable pyrazolopyridinylpyrimidine compound that acts as a selective and potent stimulator of soluble guanylate cyclase (effective dose ~ 0.1 nM to 100 µM using recombinant soluble guanylate cyclase). The mode of activation is NO-independent and appears to be mediated through direct binding to the α1 and α2 subunits. Shown to be effective in treating numerous cardiovascular conditions in animal models. Inhibits phenylephrine-induced constriction of rabbit aortic rings (IC50 = 304 nM) and blocks collagen-induced aggregation of human platelets (IC50 = 36 nM). Does not inhibit phosphodiesterases. 包装 5 mg in Plastic ampoule 生化/生理作用 Cell permeable: yes 警告 Toxicity: Standard Handling (A) 重悬 Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. 其他说明 Boerrigter, G., et al. 2003. Circulation107, 686. 法律信息 CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||
| 497507 | Fluorochem | 5-Cyclopropyl-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-amine | 95+% | 21252元/250mg; 53130元/1g; | 展开 | ||||||||||||||||||||||||||||||||
基本信息
| |||||||||||||||||||||||||||||||||||||